A new position statement from the American Academy of Sleep Medicine suggests clinicians should prioritize the evaluation and ...

Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate ...

Melbourne, Australia, April 16, 2025 (GLOBE NEWSWIRE) -- iNGENū CRO, a specialist Contract Research Organization with deep expertise in the ...

If so, it might not just be regular fatigue, it could be Idiopathic Hypersomnia (IH). This neurological sleep disorder causes overwhelming daytime drowsiness, making it difficult to stay awake and ...

Secondary endpoints of the Vibrance-3 study are changes in the Idiopathic Hypersomnia Severity Scale ... also being developed for the treatment of narcolepsy type 1 and type 2.

Secondary endpoints include change in Idiopathic Hypersomnia Severity Scale (IHSS ... the safety and efficacy of ALKS 2680 in adults with narcolepsy type 1 (NCT06358950) and narcolepsy type ...

This cohort of 351 patients with narcolepsy treated with sodium ... overall comorbidities (unadjusted analysis), except for idiopathic hypersomnia and fatigue. After adjusting the analysis to ...

DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to ...